- Home
- IMUX vs RPTX Comparison
IMUX vs RPTX Comparison
Compare IMUX & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- RPTX
- Stock Information
- Founded
- IMUX 2016
- RPTX 2016
- Country
- IMUX United States
- RPTX Canada
- Employees
- IMUX N/A
- RPTX N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- RPTX Health Care
- Exchange
- IMUX Nasdaq
- RPTX Nasdaq
- Market Cap
- IMUX 67.8M
- RPTX 63.9M
- IPO Year
- IMUX N/A
- RPTX 2020
- Fundamental
- Price
- IMUX $0.81
- RPTX $1.55
- Analyst Decision
- IMUX Strong Buy
- RPTX Strong Buy
- Analyst Count
- IMUX 6
- RPTX 3
- Target Price
- IMUX $11.60
- RPTX $4.50
- AVG Volume (30 Days)
- IMUX 1.7M
- RPTX 93.2K
- Earning Date
- IMUX 08-07-2025
- RPTX 08-05-2025
- Dividend Yield
- IMUX N/A
- RPTX N/A
- EPS Growth
- IMUX N/A
- RPTX N/A
- EPS
- IMUX N/A
- RPTX N/A
- Revenue
- IMUX N/A
- RPTX $1,073,000.00
- Revenue This Year
- IMUX N/A
- RPTX N/A
- Revenue Next Year
- IMUX N/A
- RPTX N/A
- P/E Ratio
- IMUX N/A
- RPTX N/A
- Revenue Growth
- IMUX N/A
- RPTX N/A
- 52 Week Low
- IMUX $0.56
- RPTX $0.89
- 52 Week High
- IMUX $2.11
- RPTX $4.29
- Technical
- Relative Strength Index (RSI)
- IMUX 53.22
- RPTX 67.87
- Support Level
- IMUX $0.68
- RPTX $1.40
- Resistance Level
- IMUX $0.83
- RPTX $1.45
- Average True Range (ATR)
- IMUX 0.06
- RPTX 0.05
- MACD
- IMUX 0.02
- RPTX 0.01
- Stochastic Oscillator
- IMUX 83.10
- RPTX 80.27
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.